All In Biotech

Drug Trial Radar · NCT05609942

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

9

Actual

Start

Sep 25, 2023

Primary completion

Jan 14, 2025

Study completion Mar 10, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to answer are: * Determine Recommended Dose of elenestinib (BLU-263) monotherapy for participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) monotherapy * Efficacy of elenestinib (BLU-263) monotherapy in participants with AdvSM * Determine Recommended Dose of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) in combination with azacitidine * Efficacy of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM The estimated study duration for each participant will be approximately 4 years: 2 years of treatment followed by 2 years of follow-up. Participants may be required to attend monthly visits for the first six months, followed by quarterly visits for the remainder of the study.

Conditions

  • Advanced Systemic Mastocytosis

Interventions

  • BLU-263Drug

    BLU-263 Oral Tablets

  • AzacitidineDrug

    Azacitidine powder for suspension for intravenous infusion / subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of Dose-limiting Toxicities (DLTs) (monotherapy only)Time frame: 28 Days
  2. Dose Escalation: Number of DLTs (combination therapy only)Time frame: 28 Days
  3. Dose Escalation and Expansion: Pure Pathological Response (PPR) Rate for SM in Selective KIT Inhibitor-naïve Participants (monotherapy only)Time frame: Up to approximately 4 years
  4. Dose Escalation and Expansion: Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 4 years
  5. Dose Escalation and Expansion: Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to approximately 4 years

Locations

11 sites in 7 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Palo Alto, California

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Antwerp University Hospital

    Edegem, Belgium

  • University Hospital Ghent

    Ghent, Belgium

  • CHU Caen - Institut d'Hematologie de Basse Normandie

    Caen, France

  • University Medical Centre Mannheim

    Mannheim, Germany

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Oslo University Hospital

    Oslo, Norway

  • Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast)

    Toledo, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.